Hyperglycemia in Medical Technology
Navigation Links
Hyperglycemia in Medical Technology
... (sugar) control for critical care patients with hyperglycemia (high blood glucose) does not improve outcomes ... national movement viewing the management of hyperglycemia in hospitals as a quality care measure," Dr. Etie ... and up-to-date recommendations for treatment of hyperglycemia in the hospital.
"The central goal of the ...
... either with or without diabetes, developed hyperglycemia of grade 2 or higher (P=0.002 for diabetic ... (P=0.675). However, the development of hyperglycemia or hypercholesterolemia did not have affect on ... The use of TORISEL is likely to result in hyperglycemia and hyperlipemia. This may result in the need for ...
... TD may remit, partially or completely hyperglycemia and diabetes mellitus -- Hyperglycemia, in some ... testing. Patients who develop symptoms of hyperglycemia should also undergo fasting blood glucose testing. There have been few reports of hyperglycemia with ABILIFY ABILIFY may be associated with ...
... partially or completely, if antipsychotic treatment is withdrawn. hyperglycemia and Diabetes: Hyperglycemia, some cases extreme and associated with ... at the beginning of and during treatment. Patients who develop symptoms of hyperglycemia should also undergo fasting blood glucose testing. ...
... in ICU settings. "We are witnessing an evolution in the management of hyperglycemia in inpatient settings," Dr. Etie S. Moghissi, AACE Chair of the Inpatient ... to discharge from the hospital. "The responsibility for management of hyperglycemia shifts from the health care team to the patient following hospital ...
... during treatment with TORISEL. The use of TORISEL is likely to result in hyperglycemia and hyperlipemia. This may result in the need for an increase in the dose ... abnormalities (incidence greater than or equal to 30%) are anemia (94%), hyperglycemia (89%), hyperlipemia (87%), hypertriglyceridemia (83%), elevated alkaline ...
... during treatment with TORISEL. The use of TORISEL is likely to result in hyperglycemia and hyperlipemia. This may result in the need for an increase in the dose ... abnormalities (incidence greater than or equal to 30%) are anemia (94%), hyperglycemia (89%), hyperlipemia (87%), hypertriglyceridemia (83%), elevated alkaline ...
... of and periodically during treatment. Patients who develop symptoms of hyperglycemia should also undergo fasting blood glucose testing. A potentially fatal ... (7% vs 5%). In long-term clinical trials of quetiapine, hyperglycemia (fasting glucose greater than or equal to 126 mg/dL) was observed in 10.7% ...
... of and periodically during treatment. Patients who develop symptoms of hyperglycemia should also undergo fasting blood glucose testing. A potentially fatal ... (7% vs 5%). In long-term clinical trials of quetiapine, hyperglycemia (fasting glucose greater than or equal to 126 mg/dL) was observed in 10.7% ...
... of and periodically during treatment. Patients who develop symptoms of hyperglycemia should also undergo fasting blood glucose testing. A potentially fatal ... (7% vs 5%). In long-term clinical trials of quetiapine, hyperglycemia (fasting glucose greater than or equal to 126 mg/dL) was observed in 10.7% ...
... Monia, S. Bhanot. A Newly Identified Role of Nuclear Receptor Corepressor, SMRT (Silencing Mediator of Retinoid and Thyroid) in Improving hyperglycemia and Insulin Sensitivity in Obese and Diabetic Mice (Late-Breaking Poster) Authors: S.K. Pandey, S.F. Murray, S. Guo, L.M. Watts, S.L. Booten, ...
... adverse events were biliary disorders (62%), gastrointestinal disorders (14% to 38%), and injection-site pain (20% to 50%). Hypoglycemia (4%), hyperglycemia (27%), sinus bradycardia (19%), conduction abnormalities (9%), and arrhythmias (3%) have been reported. Additional adverse reactions identified in ...
... control; those with risk factors for diabetes should undergo baseline and periodic fasting blood glucose testing. Patients who develop symptoms of hyperglycemia during treatment should undergo fasting blood glucose testing. Undesirable alterations in lipids have been observed with olanzapine ...
... vomiting (21%). The most common ( > 10%) Grade 3/4 adverse reactions were thrombocytopenia (28%), neutropenia (28%), elevated lipase (15%), and hyperglycemia (11%). In accelerated phase patients, the most commonly reported adverse reactions ( > 10%) were rash (28%), pruritus (20%), and constipation ...
... and vomiting (21%). The most common (>10%) Grade 3/4 adverse reactions were thrombocytopenia (28%), neutropenia (28%), elevated lipase (15%) and hyperglycemia (11%). In accelerated phase patients, the most commonly reported adverse reactions (>10%) were rash (28%), pruritus (20%) and constipation (18%). ...
... who are starting on atypical antipsychotics should undergo baseline and periodic fasting blood glucose testing. Patients who develop symptoms of hyperglycemia during treatment should undergo fasting blood glucose testing. Undesirable alterations in lipids have been observed with olanzapine use. Clinical ...
... diluted or mixed with any other insulin preparations or used in insulin infusion pumps. Inadequate dosing or discontinuation of treatment may lead to hyperglycemia and, in patients with type 1 diabetes, diabetic ketoacidosis. Insulin may cause sodium retention and edema, particularly if previously poor metabolic ...
... and vomiting (21%). The most common ( >10%) Grade 3/4 adverse reactions were thrombocytopenia (28%), neutropenia (28%), elevated lipase (15%), and hyperglycemia (11%). In accelerated phase patients, the most commonly reported adverse reactions ( >10%) were rash (28%), pruritus (20%), and constipation (18%). ...
... to the outpatient clinic facilitated by a diabetes care coordinator. Approximately 40% of adult hospitalized patient at University Hospital have hyperglycemia with only 5% receiving follow-up outpatient care in the diabetes clinic. The University Hospital's goal is to fill the gap in their diabetes care by ...
... newly diagnosed hyperglycemia (as defined by having an HbA1c of greater than 6.0 percent or a new fasting glucose of more than 110mg/dL). Worsening hyperglycemia (defined as greater than a one percent increase in HbA1c) was 37 percent less likely (p<0.001) in the Ranexa treated group and no increased ...
... encephalopathy in patients with deficiencies in enzymes of the urea cycle. The most common adverse reactions are vomiting (9%), hypokalemia (7%), hyperglycemia (7%), convulsions (6%), and mental impairments (6%). Do not administer to patients with known hypersensitivity to sodium phenylacetate or ...
... treated with aripiprazole - hyperglycemia and diabetes mellitus-Hyperglycemia, in some ... testing. Patients who develop symptoms of hyperglycemia should also undergo fasting blood glucose testing. There have been few reports of hyperglycemia with aripiprazole Aripiprazole may be ...
... dyspnea (20% vs 15%), tremor (20% vs 7%), decreased weight (18% vs 14%), thrombocytopenia (17% vs 10%), rash (16% vs 8%), back pain (15% vs 14%), hyperglycemia (15% vs 14%), and muscle weakness (15% vs 15%). Myelodysplastic Syndromes: Other adverse reactions reported in del 5q MDS patients (REVLIMID(R)): ...
... are at risk for diabetes should undergo fasting blood glucose testing at the beginning of and during treatment. Patients who develop symptoms of hyperglycemia should also undergo fasting blood glucose testing. Precautions include the risk of seizures, orthostatic hypotension, and cataracts. Examination of ...
... diluted or mixed with any other insulin preparations or used in insulin infusion pumps. Inadequate dosing or discontinuation of treatment may lead to hyperglycemia and, in patients with type 1 diabetes, diabetic ketoacidosis. Insulin may cause sodium retention and edema, particularly if previously poor metabolic ...
... or mixed with any other insulin preparations or used in insulin infusion pumps. Inadequate dosing or discontinuation of treatment may lead to hyperglycemia and, in patients with type 1 diabetes, diabetic ketoacidosis. Insulin may cause sodium retention and edema, particularly if previously poor ...
... either with or without diabetes, developed hyperglycemia of grade 2 or higher (P=0.002 for diabetic ... (P=0.675). However, the development of hyperglycemia or hypercholesterolemia did not have affect on ... The use of TORISEL is likely to result in hyperglycemia and hyperlipemia. This may result in the need for ...
... TD may remit, partially or completely hyperglycemia and diabetes mellitus -- Hyperglycemia, in some ... testing. Patients who develop symptoms of hyperglycemia should also undergo fasting blood glucose testing. There have been few reports of hyperglycemia with ABILIFY ABILIFY may be associated with ...
FDA Advisory Committee Votes in Favor of Zyprexa for Two Adolescent Indications
... treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, palyphagia, and weakness. Patients who develop symptoms of hyperglycemia during treatment should undergo fasting blood glucose testing. ...... partially or completely, if antipsychotic treatment is withdrawn. hyperglycemia and Diabetes: Hyperglycemia, some cases extreme and associated with ... at the beginning of and during treatment. Patients who develop symptoms of hyperglycemia should also undergo fasting blood glucose testing. ...
... in ICU settings. "We are witnessing an evolution in the management of hyperglycemia in inpatient settings," Dr. Etie S. Moghissi, AACE Chair of the Inpatient ... to discharge from the hospital. "The responsibility for management of hyperglycemia shifts from the health care team to the patient following hospital ...
... during treatment with TORISEL. The use of TORISEL is likely to result in hyperglycemia and hyperlipemia. This may result in the need for an increase in the dose ... abnormalities (incidence greater than or equal to 30%) are anemia (94%), hyperglycemia (89%), hyperlipemia (87%), hypertriglyceridemia (83%), elevated alkaline ...
... during treatment with TORISEL. The use of TORISEL is likely to result in hyperglycemia and hyperlipemia. This may result in the need for an increase in the dose ... abnormalities (incidence greater than or equal to 30%) are anemia (94%), hyperglycemia (89%), hyperlipemia (87%), hypertriglyceridemia (83%), elevated alkaline ...
... of and periodically during treatment. Patients who develop symptoms of hyperglycemia should also undergo fasting blood glucose testing. A potentially fatal ... (7% vs 5%). In long-term clinical trials of quetiapine, hyperglycemia (fasting glucose greater than or equal to 126 mg/dL) was observed in 10.7% ...
... of and periodically during treatment. Patients who develop symptoms of hyperglycemia should also undergo fasting blood glucose testing. A potentially fatal ... (7% vs 5%). In long-term clinical trials of quetiapine, hyperglycemia (fasting glucose greater than or equal to 126 mg/dL) was observed in 10.7% ...
... of and periodically during treatment. Patients who develop symptoms of hyperglycemia should also undergo fasting blood glucose testing. A potentially fatal ... (7% vs 5%). In long-term clinical trials of quetiapine, hyperglycemia (fasting glucose greater than or equal to 126 mg/dL) was observed in 10.7% ...
Wyeth's TORISEL Receives European Commission Approval for the Treatment of Advanced Kidney Cancer
... during treatment with TORISEL. The use of TORISEL is likely to result in hyperglycemia and hyperlipemia. This may result in the need for an increase in the dose ... abnormalities (incidence greater than or equal to 30%) are anemia (94%), hyperglycemia (89%), hyperlipemia (87%), hypertriglyceridemia (83%), elevated alkaline ...SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia
... of and periodically during treatment. Patients who develop symptoms of hyperglycemia should also undergo fasting blood glucose testing. A potentially fatal ... hypotension (7% vs 5%). In long-term clinical trials of quetiapine, hyperglycemia (fasting glucose Greater Than or Equal To 126 mg/dl) was observed in 10.7% ...... Monia, S. Bhanot. A Newly Identified Role of Nuclear Receptor Corepressor, SMRT (Silencing Mediator of Retinoid and Thyroid) in Improving hyperglycemia and Insulin Sensitivity in Obese and Diabetic Mice (Late-Breaking Poster) Authors: S.K. Pandey, S.F. Murray, S. Guo, L.M. Watts, S.L. Booten, ...
Boehringer Ingelheim Unveils Diabetes Pipeline
... 2 diabetes patients when added to onogoing metformin therapy. ADA, 05-09 June 2009, New Orleans, U.S.A. (2) Nathan DM et al. Medical Management of hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy. Diabetes Care 21:1-11, 2008. (3) Clinicaltrials.gov. ...... adverse events were biliary disorders (62%), gastrointestinal disorders (14% to 38%), and injection-site pain (20% to 50%). Hypoglycemia (4%), hyperglycemia (27%), sinus bradycardia (19%), conduction abnormalities (9%), and arrhythmias (3%) have been reported. Additional adverse reactions identified in ...
... control; those with risk factors for diabetes should undergo baseline and periodic fasting blood glucose testing. Patients who develop symptoms of hyperglycemia during treatment should undergo fasting blood glucose testing. Undesirable alterations in lipids have been observed with olanzapine ...
... vomiting (21%). The most common ( > 10%) Grade 3/4 adverse reactions were thrombocytopenia (28%), neutropenia (28%), elevated lipase (15%), and hyperglycemia (11%). In accelerated phase patients, the most commonly reported adverse reactions ( > 10%) were rash (28%), pruritus (20%), and constipation ...
... and vomiting (21%). The most common (>10%) Grade 3/4 adverse reactions were thrombocytopenia (28%), neutropenia (28%), elevated lipase (15%) and hyperglycemia (11%). In accelerated phase patients, the most commonly reported adverse reactions (>10%) were rash (28%), pruritus (20%) and constipation (18%). ...
... who are starting on atypical antipsychotics should undergo baseline and periodic fasting blood glucose testing. Patients who develop symptoms of hyperglycemia during treatment should undergo fasting blood glucose testing. Undesirable alterations in lipids have been observed with olanzapine use. Clinical ...
... diluted or mixed with any other insulin preparations or used in insulin infusion pumps. Inadequate dosing or discontinuation of treatment may lead to hyperglycemia and, in patients with type 1 diabetes, diabetic ketoacidosis. Insulin may cause sodium retention and edema, particularly if previously poor metabolic ...
... and vomiting (21%). The most common ( >10%) Grade 3/4 adverse reactions were thrombocytopenia (28%), neutropenia (28%), elevated lipase (15%), and hyperglycemia (11%). In accelerated phase patients, the most commonly reported adverse reactions ( >10%) were rash (28%), pruritus (20%), and constipation (18%). ...
Drug Combo Could Lower Diabetes Complications and Costs
... diabetes have health implications for mother and child that extend far beyond pregnancy. However, for women with pre-existing diabetes, maternal hyperglycemia that exists prior to pregnancy and continues into the first 8 weeks of gestation exposes the fetus to an increased risk of miscarriage and birth ...... to the outpatient clinic facilitated by a diabetes care coordinator. Approximately 40% of adult hospitalized patient at University Hospital have hyperglycemia with only 5% receiving follow-up outpatient care in the diabetes clinic. The University Hospital's goal is to fill the gap in their diabetes care by ...
... newly diagnosed hyperglycemia (as defined by having an HbA1c of greater than 6.0 percent or a new fasting glucose of more than 110mg/dL). Worsening hyperglycemia (defined as greater than a one percent increase in HbA1c) was 37 percent less likely (p<0.001) in the Ranexa treated group and no increased ...
... encephalopathy in patients with deficiencies in enzymes of the urea cycle. The most common adverse reactions are vomiting (9%), hypokalemia (7%), hyperglycemia (7%), convulsions (6%), and mental impairments (6%). Do not administer to patients with known hypersensitivity to sodium phenylacetate or ...
Aptivus(R) (tipranavir) Capsules Granted Full Approval by the U.S. FDA
... with caution in patients with a known sulfonamide allergy. -- New onset diabetes mellitus, exacerbation of pre-existing diabetes mellitus, hyperglycemia and increased bleeding (in patients with hemophilia) have been reported in patients taking protease inhibitors. A causal relationship between ...DiObex Begins Dosing Patients in Phase 2b Trial of Type 2 Diabetes Drug
... Preclinical and clinical studies have suggested that a link exists between high cortisol levels and visceral adiposity, insulin resistance, and hyperglycemia -- common elements of T2DM and metabolic syndrome. There are no cortisol synthesis inhibitors on the market today, potentially making DIO-902 a ...One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function
... M, Strumph P, Pimenta W, Veneman T, Jenssen T and Bolli G. "Simultaneous assessment of insulin secretion and insulin sensitivity using a hyperglycemia clamp." J Clin Endocrinol Metab 1992: 75(2), 379-382. 4 The International Diabetes Federation Diabetes Atlas. Available at: ....One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function
... M, Strumph P, Pimenta W, Veneman T, Jenssen T and Bolli G. "Simultaneous assessment of insulin secretion and insulin sensitivity using a hyperglycemia clamp." J Clin Endocrinol Metab 1992: 75(2), 379-382. 4 The International Diabetes Federation Diabetes Atlas. Available at: ....... treated with aripiprazole - hyperglycemia and diabetes mellitus-Hyperglycemia, in some ... testing. Patients who develop symptoms of hyperglycemia should also undergo fasting blood glucose testing. There have been few reports of hyperglycemia with aripiprazole Aripiprazole may be ...
Investigational Study Evaluates the Effectiveness of Aripiprazole in Adolescents With Schizophrenia
... treated with aripiprazole -- hyperglycemia and diabetes mellitus -- Hyperglycemia, in some ... testing. Patients who develop symptoms of hyperglycemia should also undergo fasting blood glucose testing. There have been few reports of hyperglycemia with aripiprazole Aripiprazole may be ...... dyspnea (20% vs 15%), tremor (20% vs 7%), decreased weight (18% vs 14%), thrombocytopenia (17% vs 10%), rash (16% vs 8%), back pain (15% vs 14%), hyperglycemia (15% vs 14%), and muscle weakness (15% vs 15%). Myelodysplastic Syndromes: Other adverse reactions reported in del 5q MDS patients (REVLIMID(R)): ...
... are at risk for diabetes should undergo fasting blood glucose testing at the beginning of and during treatment. Patients who develop symptoms of hyperglycemia should also undergo fasting blood glucose testing. Precautions include the risk of seizures, orthostatic hypotension, and cataracts. Examination of ...
Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer Treatment
... (6%); creatinine elevation (5%); alopecia (1%-13%); and dyspnea (1%-7%). The most common adverse events (all grades) were paresthesias (38%); hyperglycemia (30%); infection (18%-28%); and constipation (17%-28%). The most severe adverse events (grades 3/4) with GEMZAR plus carboplatin for the treatment ...... diluted or mixed with any other insulin preparations or used in insulin infusion pumps. Inadequate dosing or discontinuation of treatment may lead to hyperglycemia and, in patients with type 1 diabetes, diabetic ketoacidosis. Insulin may cause sodium retention and edema, particularly if previously poor metabolic ...
... or mixed with any other insulin preparations or used in insulin infusion pumps. Inadequate dosing or discontinuation of treatment may lead to hyperglycemia and, in patients with type 1 diabetes, diabetic ketoacidosis. Insulin may cause sodium retention and edema, particularly if previously poor ...
Other ContentsvariancevariancevariancephenotypicphenotypicphenotypicphenotypicphosphatasephosphatasephosphatasephosphatasephosphatasephosphatasephosphatasegroupgroupgroupgroupgroupgroupgroupgroupgroupgroupphosphodiesterphosphodiesterphotophosphorylationOther TagsSECSECSECSECSECSECSECSECLMaxDispenseDispense
(Date:12/1/2009)...eaking, ants have two different feeding strategies...ous," meaning that they are generalist predators f...ir remains. Some, however, are "herbivorous". Th..., the bulk of their diets consist of plant-derived... produced by plants to attract ants, called extra-...
(Date:12/1/2009)..., SUNNYVALE, Calif., Dec. 1 Gest..., Release 3.0 - a turnkey, portable, plug and play...sing, exhibits, entertainment and touring promotio...s of patents in camera-enabled gesture recognition...and entertainment systems. ,, Guaranteed for qu...
(Date:12/1/2009)...Ohio Ohio State University cancer researchers hav...ls brain-tumor cells and blocks the growth of new ... viruses designed to kill cancer cells oncolytic ...e brain tumors if they also carry a gene for a pro...tein, called vasculostatin, is normally produced i...
Breaking Biology News(10 mins):Bacterial gut symbionts are tightly linked with the evolution of herbivory in ants 2GestureTek Unveils The CUBE V3 Portable, Plug and Play Interactive Projection Display System for Advertising and Exhibits 2Tumor-attacking virus strikes with 'one-two punch' 2PrepareCo com Introduces New Online Source for Emergency Self Reliant Food 26amp 3B Survival Products 60151 1PrepareCo com Introduces New Online Source for Emergency Self Reliant Food 26amp 3B Survival Products 60151 2Soligenix to Present at 8th Annual BIO Investor Forum 14615 1Soligenix to Present at 8th Annual BIO Investor Forum 14615 2Soligenix to Present at 8th Annual BIO Investor Forum 14615 3Soligenix to Present at 8th Annual BIO Investor Forum 14615 4NYU Poly Launches Unique Undergrad Forum on Invention Innovation and Entrepreneurship 14613 1NYU Poly Launches Unique Undergrad Forum on Invention Innovation and Entrepreneurship 14613 2NYU Poly Launches Unique Undergrad Forum on Invention Innovation and Entrepreneurship 14613 3NYU Poly Launches Unique Undergrad Forum on Invention Innovation and Entrepreneurship 14613 4(Date:12/2/2009)... myEMRchoice.com Enables Personal Healt... Fort Washington, PA (PRWEB) December ... consumers is to read their own medical records. W...ping control of personal medical records is easier... based healthcare technology company has added ser...
(Date:12/2/2009)..., CAMPBELL, Calif., Dec. 1 Last ...how, Dr. Rafael Pelayo, Associate Professor at the...rsity School of Medicine, recommended the Ecotones...ep plan for people trying to achieve a better nigh...ound noise is a problem for people when they are s...
(Date:12/2/2009)...OHANNESBURG, Dec. 2 LeapFrog Inves...illion) investment in AllLife, the innovative Sout...nd diabetes. The investment brings together LeapFr...d AllLife, one of Africa,s most innovative insuran...orld AIDS Day. ,, "AllLife has developed a dist...
(Date:12/1/2009)... Threaded Metal Housing Enables a Posit... Minneapolis, Minnesota (Vocus) -- Omnetic...miniature connectors, has announced the addition o...mily of products. These are the smallest Mil-Qual... provides a positive lock while compressing an o-r...
(Date:12/1/2009)..., NEW YORK, Dec. 1 Reportlinker...s available in its catalogue: ,, The Future of... Competitive Benchmarking, Product Pipeline and De...0166816/The-Future-of-Monoclonal-Antibodies---Mark...uct-Pipeline-and-Deals-Analysis.html ,, Summ...
Breaking Medicine News(10 mins):Health News:Personal Health Records On-Demand, In Your Pocket 2Health News:Sleep Specialist Dr. Rafael Pelayo Recommends ASTI's Ecotones Duet Sleep Sound Machine 2Health News:Sleep Specialist Dr. Rafael Pelayo Recommends ASTI's Ecotones Duet Sleep Sound Machine 3Health News:LeapFrog Invests $6M in AllLife, Innovative African HIV and Diabetes Insurer 2Health News:LeapFrog Invests $6M in AllLife, Innovative African HIV and Diabetes Insurer 3Health News:Omnetics Announces Newest Addition to Nano Circular Family 2Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 2Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 3Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 4Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 5Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 6Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 7Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 8Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 9Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 10Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 11Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 12Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 13[0] Personal Health Records On-Demand, In Your Pocket [0] Sleep Specialist Dr. Rafael Pelayo Recommends ASTI's Ecotones Duet Sleep Sound Machine[0] LeapFrog Invests $6M in AllLife, Innovative African HIV and Diabetes Insurer[0] Omnetics Announces Newest Addition to Nano Circular Family [1] Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
SECExclusionDYEnamicMultiDosePrednisoneIntegralmuscarinicCLIPRDilutionsLMaxDispenseDissolutionMeasurementsAbsorbance
Other Tagswood 2invested 2invested 3invested 4was 2was 3was 4was 5was 6was 7was 8was 9was 10easier 2easier 3easier 4easier 5easier 6easier 7easier 8alter 2alter 3alter 4alter 5alter 6alter 7alter 8alter 9
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |